Schering-Plough Noxafil Review Prolonged By Last-Minute Label, Data Integrity Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA review documents for the antifungal illustrate an unusual case of the agency missing the user fee target for a priority review application.